Therapeutic importance of garlic supplementation in the management of nonalcoholic fatty liver disease: A systematic review of preclinical studies

Background : Non-alcoholic fatty liver disease (NAFLD) is considered as the most widely recognized incessant liver problem. It is accepted to be the hepatic segment of the metabolic disorder. Numerous treatment approaches have been proposed, the most encouraging of which are those with way of life interventions. This preclinical review was performed due to lack of articles on human subject during the literature search. This systematic review will help to explore basic concepts about the mechanisms by which garlic supplementation suppresses NAFLD. Objective : The aim of this systematic review was to evaluate the therapeutic importance of garlic supplementation in NAFLD. Methods : The PUBMED, Cochrane central library and Google Scholar were searched. The search items were limited to only randomize controlled preclinical trials with English language irrespective of species, age, gender and time. In vitro and human studies were excluded. Key outcomes were a change in serum transaminase, body weight and liver histochemistry. Results : Initial searching retrieved 13,341 peer-reviewed articles and abstracts. Eight studies met all inclusion criteria. The review included a total of 361 animal models. Following delivery of garlic extracts, a decrease in serum transaminases, a reduction of high fat diet induced hepatic lipid and body weight was observed. Additional outcomes like a reduction of pro-inflammatory cytokines and oxidative stress markers and an enhancement of antioxidative enzymes were seen in some of the studies. Conclusion : The decrease in a key biochemical marker of liver damage following treatment with garlic extracts, as well as improvements in liver histochemistry, suggests that these agents may be effective alternatives for managing NAFLD. of and/or tissue decrement of lipolysis markers. of lipogenic SREBP1c FAS in HFD SREBP1c upregulated by activating cholesterol synthesis and FAS) TG synthesis(glycerophosphate acyl SREBP1c downregulated lipolysis markers, of CPT-1and